Stocks To Watch: ION Geophysical Corporation (IO) And Adamas Pharmaceuticals, Inc. (ADMS) In The Spotlight

The price of ION Geophysical Corporation (NYSE:IO) went up by $0.27 now trading at $10.35. Their shares witnessed a 128.48% increase from the 52-week low price of $4.53 they recorded on 2018-12-26. Even though it is still -184.06% behind the $29.4 high touched on 2018-05-17. The last few days have been rough for the stock, as its price has decreased by -7.42% during the week. It has also performed poorly over the past three months, as it lost around -15.65% while it has so far retreated around -61.67% during the course of a year. The stock of IO recorded 99.81% uptrend from the beginning of this year till date. The 12-month potential price target for ION Geophysical Corporation is set at $25. This target means that the stock has an upside potential to increase by 141.55% from the current trading price.

18 institutions entered new ION Geophysical Corporation (NYSE:IO) positions, 33 added to their existing positions in these shares, 34 lowered their positions, and 13 exited their positions entirely.

ION Geophysical Corporation (IO) trade volume has increased by 21.67% as around 202,593 shares were sold when compared with its 50-day average volume of traded shares which is 166,504. At the moment, IO is witnessing a downtrend, as it is trading -15.96% below its 20-day SMA, -25.59% below its 50-day SMA, and -18.76% below its 200-day SMA. The company runs an ROE of roughly -170.7%, with financial analysts predicting that their earnings per share growth will be around 18% per annum for the next five year. This will be compared to the 26.3% increase witnessed over the past five years.

The first technical resistance point for ION Geophysical Corporation (NYSE:IO) will likely come at $10.94, marking a 5.39% premium to the current level. The second resistance point is at $11.53, about 10.23% premium to its current market price. On the other hand, inability to breach the immediate hurdles can drag it down to $9.26, the lower end of the range. IO’s 14-day MACD is -1.36 and this negative figure indicates a downward trading trend. The company’s 14-day RSI (relative strength index) score is 36.87, which shows that its stock has been neutral. The 20-day historical volatility for the stock stands at 80.61 percent, which is low when compared to that of the 50-day’s 84.83 percent.

The shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has increased by 4.37%, and now trading at $5.73 on the Wall Street in the intra-day deal, with their shares traded now around 382,316. This is a decline of -99,666 shares over the average 481,982 shares that were traded daily over the last three months. The stock that is trading at $5.73 went higher by 6.9% from its 52-week low of $5.36 that it attained back on 2019-05-10. The stock recorded a 52-week high of $32.9 nearly 363 days ago on 2018-05-18.

ADMS stock hasn’t performed well over the past 30 days, as it lost -10.89% while its price plunged by -32.9% year-to-date (YTD). Looking at the last few days, it has been tough for the stock, as it tumbled -4.02% over the last week. The stock’s 12-month potential target price is now at $28.78. This means that the stock price might likely increase by 402.27% from its current trading price. 7 out of 11 Wall Street analysts which represents 63.64% rated the stock as a buy while the remaining 27.27% rated it as a hold, with 9.09% of analysts rating it as a sell.

Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has been utilizing an ROE that is roughly -122.4%, with stock analysts predicting that the company’s EPS for the next five years will go up by 32.2% per year, following the -29% drop that was witnessed during the past five years. The stock at the moment is on a downtrend, trading -7.24% below its 20-day SMA, -16.68% below its 50-day SMA, and -55.4% below its 200-day SMA. In percentage terms, the aggregate Adamas Pharmaceuticals, Inc. shares held by institutional investors is 0%. 18 institutions jumped in to acquire Adamas Pharmaceuticals, Inc. (ADMS) fresh stake, 53 added to their current holdings in these shares, 54 lowered their positions, and 27 left no stake in the company.

The stock’s 9-day MACD is -0.32 and this negative figure indicates a downward trading trend. The company’s 9-day RSI score is 34.26, which shows that its stock has been neutral. The 20-day historical volatility for the shares stand at 38.92 percent, which is more when compared to that of the 50-day’s 36.91 percent. On the daily chart, we see that the stock could reach the first level of resistance at $5.88, sporting a 2.55% premium to the current level. The next resistance point is at $6.03, representing nearly 4.98% premium to the current market price of Adamas Pharmaceuticals, Inc. (ADMS). On the other hand, failure to breach the immediate hurdles can drag it down to $5.22, the lower end of the range.